Show simple item record

dc.creatorFederico, M
dc.creatorSymonds, CE
dc.creatorBagella, L
dc.creatorRizzolio, F
dc.creatorFanale, D
dc.creatorRusso, A
dc.creatorGiordano, A
dc.date.accessioned2021-02-01T00:01:15Z
dc.date.available2021-02-01T00:01:15Z
dc.date.issued2010-08-04
dc.identifier.issn1476-4598
dc.identifier.issn1476-4598
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/5518
dc.identifier.other20684776 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/5536
dc.description.abstractBackground: CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly upregulated under genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2 for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this switch, we analyzed the effects of the CDK-inhibitor R-Roscovitine on the expression levels of cyclin A1 under genotoxic stress and observed subsequent DNA damage and repair mechanisms.Results: We found that R-Roscovitine alone was unable to alter cyclin A1 transcriptional levels, however it was able to reduce protein expression through a proteosome-dependent mechanism. When combined with DNA damaging agents, R-Roscovitine was able to prevent the DNA damage-induced upregulation of cyclin A1 on a transcriptional and post-transcriptional level. This, moreover resulted in a significant decrease in non-homologous end-joining (NHEJ) paired with an increase in DNA DSBs and overall DNA damage over time. Furthermore, microarray analysis demonstrated that R-Roscovitine affected DNA repair mechanisms in a more global fashion.Conclusions: Our data reveal a new mechanism of action for R-Roscovitine on DNA repair through the inhibition of the molecular switch between cyclin A family members under genotoxic conditions resulting in reduced NHEJ capability. © 2010 Federico et al; licensee BioMed Central Ltd.
dc.format.extent208-208
dc.language.isoen
dc.relation.haspartMolecular Cancer
dc.relation.isreferencedbySpringer Science and Business Media LLC
dc.rightsCC BY
dc.subjectCyclin A1
dc.subjectDNA Damage
dc.subjectDNA Repair
dc.subjectDoxorubicin
dc.subjectHydrogen-Ion Concentration
dc.subjectProtein Kinase Inhibitors
dc.subjectPurines
dc.subjectRoscovitine
dc.subjectUp-Regulation
dc.titleR-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair
dc.typeArticle
dc.type.genreJournal Article
dc.relation.doi10.1186/1476-4598-9-208
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.creator.orcidGiordano, Antonio|0000-0002-5959-016X
dc.date.updated2021-02-01T00:01:10Z
refterms.dateFOA2021-02-01T00:01:16Z


Files in this item

Thumbnail
Name:
R-Roscovitine (Seliciclib) ...
Size:
3.444Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record